thought call
result milestones/contract revenu expect
posit outlook commerci stori remain intact inde despit
gross-to-net impact jakafi volum core indic mf pv
y/i respect franchis continu anchor near term
forecast con reflect impress compound-annual-growth-rate
inclus minim gvhd contribut beyond commerci execut
encourag improv financi disciplin overal opex spend well
quarter updat non-gaap guidanc reflect flat y/i
growth midpoint inde decis stop fund co-develop
baricitinib make sens perspect especi light increas
competit dynam see takeaway
biosimilar kol call anyth renew focu reinforc posit
addit valu could unlock refocus pipelin later-stag asset
greater strateg alignment/commerci synergi despit vitiligo result
ruxolitinib cream still seem like distract view given progress
cost structur togeth number pipelin catalyst includ gvhd data
maintain ow rate pt
pipelin updat reiter confid upcom gvhd may
pdufa result track read-out later yearalong
itacitinib follow posit phase vitiligo result phase
ruxolitinib cream set initi nda remain track pemigatinib
cholangiocarcinoma capmatinib nsclc partner novarti
model chang follow call modestli adjust
revenu forecast respect
also revis non-gaap ep estim
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight compel mix
grow commerci asset interest pipelin
asset exclud epacadostat
epacadostat key pipelin driver compani
earlier pipelin program could result
share upsid also expect jakafi peak
royalti baricitinib repres
ww compel commerci perform
success earlier pipelin asset across portfolio
assum slower jakafi growth mf pf littl
uptak gvhd et similar minim
penetr olumi ra pipelin
assum failur pipelin agent itacitinib
pemigatinib
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
